Skip to main
ANGO
ANGO logo

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc is experiencing robust growth in its Auryon product line, particularly within the office-based labs (OBL) and hospital settings, which is positively impacting its average selling prices (ASP). The company is also enhancing its gross margins, currently at 52.5%, through accelerated manufacturing initiatives and a favorable shift in revenue towards higher-margin Med-Tech products. Continued customer acquisition, increased utilization among existing accounts, and successful pricing strategies are expected to drive sustained growth for the company moving forward.

Bears say

AngioDynamics's financial outlook appears negative due to anticipated tariff headwinds estimated at $4 million to $6 million, which could adversely affect overall profitability. Furthermore, the company is bracing for increased pressure on inventory in the second half of fiscal year 2026 as a result of rising raw material costs. Despite some positive performance driven by capital sales and strong demand for NanoKnife disposables, the underlying cost pressures and external tariffs present significant risks to the company's financial stability.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.